5/11/2023
Page 2 of 5
U.S.C 263a(f)(4)(B)(vi), 42 C.F.R. 493.1274(a)). Remote review of cytology digital images is included in this
enforcement discretion. See Question 3.
However, physical slides, including pathology, being examined using a microscope that are not a digital
image, cannot be read remotely under a primary location CLIA certificate as described above. Slides must be
read at a primary site CLIA-certified laboratory.
6. If I am reviewing patient digital images and digital data remotely, can I perform proficiency testing (PT) in
the same way?
Response: Yes. As long as the remote site is operating under a primary site CLIA number, CMS would not
consider the review of PT digital data to be a PT referral since all parties were acting under a single CLIA
number.
7. Does enforcement discretion apply to PT for cytology gynecologic examinations (Pap smears)?
Response: No. Cytology gynecologic proficiency testing (PT) involves reading physical slides so this
enforcement discretion does not apply. Laboratories performing testing under the specialty of Cytology,
must follow the CMS-approved Cytology gynecologic PT program requirements and guidelines. All Cytology
PT slide reviews must occur at the primary site, under the direction of a proctor and not at different site.
8. Does this guidance apply to laboratory personnel who have already obtained CLIA certificates for their
home or other sites separate from the primary testing site?
Response: No, this guidance regarding remote sites does not apply to pathologists who have already
obtained a CLIA certificate, and are not operating under any other CLIA certificate. Laboratory personnel
who have obtained a CLIA certificate for the remote testing site may decide not to renew their CLIA
certificate; and instead, perform remote review of clinical laboratory data, results and digital images for a
primary site, as long as the criteria in QSO-23-15-CLIA are met.
9. Will the enforcement discretion for using molecular and antigen SARS-CoV-2 tests for asymptomatic
individuals continue after the PHE is declared over by the Secretary?
Response: No. The FDA has authorized numerous antigen and molecular tests, as well as a number of over-
the-counter tests that are intended for use in asymptomatic individuals. As of the publication date of this
memorandum, all CLIA-certified laboratories are required to follow the manufacturer’s Instructions for Use
(IFU), including the intended use, for SARS-CoV-2 testing. Under the CLIA regulations, modifications to a
test's IFU means the test is high complexity. However, we would not consider it a modification of the IFU
when the IFU states, for example, “individuals suspected of COVID-19 by their healthcare provider”, and the
test is ordered by the healthcare provider for asymptomatic patients. The decision if an individual is
suspected of COVID-19 is made by the healthcare provider. If a laboratory accepts referral specimens,
written instructions for specimen submission and handling must be available to the laboratory’s clients,
including specimen acceptability and rejection criteria.
If a test is modified, the laboratory must establish performance specifications as required at §493.1253(b)(2)
and meet high complexity personnel requirements in §§493.1441-1489. The laboratory director is
responsible for ensuring that the procedures used to establish performance specifications are adequate to
determine the method's accuracy, precision, and other pertinent performance characteristics and that the
test method can provide quality results. This is a return to pre-PHE regulatory requirements.